Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16281194 | 0.84 | CTSK (0.35) | CTSKHDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL5051892 | 0.84 | CTSK (0.35) | CTSKHDAC6HDAC1HDAC2NFKB1 | |
| SCHEMBL12829294 | 0.83 | HDAC6 (0.38) | CTSKHDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL7657774 | 0.83 | AAK1 (0.39) | CTSKHDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL6674299 | 0.83 | AAK1 (0.39) | CTSKHDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL7385821 | 0.83 | AAK1 (0.39) | CTSKHDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL26027926 | 0.81 | CTSK (0.38) | CTSKHDAC6HDAC1HDAC2 | |
| SCHEMBL6673921 | 0.81 | CTSK (0.35) | CTSKHDAC6HDAC1HDAC2AAK1 | |
| SCHEMBL20031035 | 0.81 | CTSK (0.33) | CTSKHDAC6HDAC1HDAC2 | |
| SCHEMBL23279459 | 0.80 | CTSK (0.35) | CTSKHDAC6HDAC1HDAC2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105585583-A | Non-peptide IAP (inhibitor of apoptosis protein) antagonist as well as synthetic method and application thereof | UNIV GUANGDONG TECHNOLOGY | 2016-05-18 | — | — | CN | claimed |
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-02 | — | — | US | disclosed |
| CN-105585583-B | A kind of non-peptides apoptosis inhibitory protein antagonist and its synthetic method and application | 广东工业大学 | 2018-04-13 | — | — | CN | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
| CN-105585583-A | Non-peptide IAP (inhibitor of apoptosis protein) antagonist as well as synthetic method and application thereof | UNIV GUANGDONG TECHNOLOGY | 2016-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | CTSK 3392/4885HDAC6 59/4885HDAC1 10/4885 |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | CTSK 3392/4885HDAC6 59/4885HDAC1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.